Sarepta's Eteplirsen Is Centerpiece Of Senate Hearing On Expanded Access
This article was originally published in The Pink Sheet Daily
Executive Summary
Witnesses call for political pressure on FDA to approve the Duchenne drug; patients and advocates also urge general approval reciprocity with Europe and incentives for pediatric trials; agency was not invited to testify.
You may also be interested in...
Political Appointees Shouldn't Influence Approval Decisions, Califf Says
FDA commissioner offers new details about why he left final decision on Sarepta's controversial Duchenne muscular dystrophy drug to FDA's expert bureaucrats.
FDA Can't Win On Guidances: Expanded Access Policy, Duchenne Worries Collide
Keeping guidances in draft form makes Congress angry, but finalizing them gives Wall Street the vapors.
Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community
Is the lack of rejection cause for optimism, or will eteplirsen end up like BioMarin's drisapersen?